QUOTE AND NEWS
FiercePharma  Apr 13  Comment 
Novartis' Gilenya patent loss sets MS market up for battle with early generics esagonowsky Thu, 04/13/2017 - 09:39
FiercePharma  Apr 13  Comment 
Look out, Biogen and Novartis. Roche's Ocrevus is coming for your MS sales—big time, analyst predicts chelfand Thu, 04/13/2017 - 08:29
Motley Fool  Apr 8  Comment 
Why the pipelines for Johnson & Johnson, Novartis, and Roche look especially strong.
The Economic Times  Apr 8  Comment 
Sources say cos have already signed a business transfer deal for the domestic women healthcare portfolio, which is worth around Rs 300 crore.
FiercePharma  Apr 7  Comment 
Greek official: 'Thousands' of people implicated in Novartis bribery probe esagonowsky Fri, 04/07/2017 - 09:42
Motley Fool  Apr 6  Comment 
Investors should keep an eye on this promising way to treat cancer.
GenEng News  Apr 6  Comment 
Novartis exercised an option to license Boston-based Lubris’s recombinant human lubricin (proteoglycan 4) candidate, ECF843, for ophthalmic indications worldwide, excluding Europe. ECF843 is in development for treating dry eye, and in a...
Financial Times  Apr 5  Comment 
Global companies including Bosch, Airbus and Novartis stress role in creating US jobs
Benzinga  Apr 5  Comment 
Steve Scala of Cowen downgraded shares of Novartis AG (ADR) (NYSE: NVS) from Outperform to Market Perform with a price target lowered to $77 from $87 as the company's strengths "now balance its risks." According to Scala's estimates, Novartis'...




 

Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki